Literature DB >> 20088940

Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals.

L F A Maurissen1, E Castoldi, P Simioni, J Rosing, T M Hackeng.   

Abstract

BACKGROUND: Protein S acts as a cofactor for full-length tissue factor pathway inhibitor (TFPI) in the downregulation of thrombin formation.
OBJECTIVE: To develop a functional test to measure the activity of the TFPI-protein S system in plasma. METHODS/PATIENTS: Using calibrated automated thrombography, we quantified the activity of the TFPI-protein S system in plasma by measuring thrombin generation in the absence and presence of neutralizing antibodies against protein S or TFPI. Moreover, we designed an enzyme-linked immunosorbent assay (ELISA) to determine the level of full-length TFPI in plasma. The performance of these assays was examined in plasma from 85 normal individuals and from 35 members of protein S-deficient families.
RESULTS: The ratio of thrombin peaks determined in the absence and presence of anti-protein S antibodies (protein S ratio = 0.5 in normal plasma) is a measure of the TFPI cofactor activity of protein S, whereas the ratio of thrombin peaks determined in the absence and presence of anti-TFPI antibodies (TFPI ratio = 0.25 in normal plasma) is a measure of the overall activity of the TFPI-protein S system. Protein S and TFPI ratios were elevated in protein S-deficient individuals, indicating an impairment of the TFPI-protein S system. Both ratios correlated well with full-length TFPI levels, which were significantly lower in protein S-deficient patients than in normal family members.
CONCLUSIONS: Functional assays for the TFPI-protein S system and an ELISA for full-length TFPI were developed. These assays show that the activity of the TFPI-protein S anticoagulant pathway is impaired in individuals with congenital protein S deficiency.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088940     DOI: 10.1111/j.1538-7836.2010.03743.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.

Authors:  Kenichi Ogiwara; Keiji Nogami; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

2.  Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.

Authors:  Sara Calzavarini; Raja Prince-Eladnani; François Saller; Luca Bologna; Laurent Burnier; Anne C Brisset; Claudia Quarroz; Maria Desiré Reina Caro; Vladimir Ermolayev; Yasuhiro Matsumura; José A Fernández; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113

3.  Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

Authors:  Elisabetta Castoldi; Lisbeth F A Maurissen; Daniela Tormene; Luca Spiezia; Sabrina Gavasso; Claudia Radu; Tilman M Hackeng; Jan Rosing; Paolo Simioni
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 4.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

Review 5.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

6.  Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use.

Authors:  Kristien Winckers; Stella Thomassen; Hugo Ten Cate; Tilman M Hackeng
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

7.  Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa.

Authors:  Anja Maag; Nienke van Rein; Tim J Schuijt; Wil F Kopatz; Danielle Kruijswijk; Stella Thomassen; Tilman M Hackeng; Rodney M Camire; Tom van der Poll; Joost C M Meijers; Mettine H A Bos; Cornelis van 't Veer
Journal:  J Thromb Haemost       Date:  2021-11-23       Impact factor: 16.036

8.  Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation.

Authors:  Freeha Arshad; Jelle Adelmeijer; Hans Blokzijl; Aad van den Berg; Robert Porte; Ton Lisman
Journal:  F1000Res       Date:  2014-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.